期刊
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
卷 3, 期 2, 页码 83-94出版社
SPRINGER
DOI: 10.1007/s11481-007-9099-6
关键词
nanomaterials; neuroregeneration; blood-brain barrier; neuroscaffolding; nanotubes; fullerenes; cell-based delivery
资金
- NCI NIH HHS [R01 CA089225-06, R01 CA116591, R01 CA116591-02, R01 CA116591-03, R01 CA89225, R01 CA089225-05, R01 CA116591-01A1, R01 CA089225] Funding Source: Medline
- NINDS NIH HHS [R01 NS051334-02, R01 NS036229-09, R01 NS036229, R01 NS051335, R01 NS051334, R01 NS36229, R01 NS051334-01A1, R01 NS036229-08, R01 NS051334-03] Funding Source: Medline
Neurodegenerative disorders including Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, and stroke are rapidly increasing as population ages. The field of nanomedicine is rapidly expanding and promises revolutionary advances to the diagnosis and treatment of devastating human diseases. This paper provides an overview of novel nanomaterials that have potential to improve diagnosis and therapy of neurodegenerative disorders. Examples include liposomes, nanoparticles, polymeric micelles, block ionomer complexes, nanogels, and dendrimers that have been tested clinically or in experimental models for delivery of drugs, genes, and imaging agents. More recently discovered nanotubes and nanofibers are evaluated as promising scaffolds for neuroregeneration. Novel experimental neuroprotective strategies also include nanomaterials, such as fullerenes, which have antioxidant properties to eliminate reactive oxygen species in the brain to mitigate oxidative stress. Novel technologies to enable these materials to cross the blood brain barrier will allow efficient systemic delivery of therapeutic and diagnostic agents to the brain. Furthermore, by combining such nanomaterials with cell-based delivery strategies, the outcomes of neurodegenerative disorders can be greatly improved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据